Compass Therapeutics, Inc. (CMPX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US20454B1044
Compass Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -72.84 m USD |
| EBIT | -72.89 m USD |
| Net income | -66.49 m USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
More stocks
- MC Mining Ltd (MCM.AX)
- Catering International & Services S.A. (ALCIS.PA)
- Seven Hills Realty Trust (SEVN)
- Drewloong Precision Inc (4572.TW)
- MPH Health Care (93M1.DE)
- Shane Global Holding Inc (8482.TW)
- Newmax Technology Co Ltd (3630.TWO)
- Hawesko Holding (HAW.DE)
- Montauk Renewables, Inc. (MNTK)
- Univacco Technology (3303.TWO)
- Appear ASA (APR.OL)
- Chant Sincere Co Ltd (6205.TW)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.